![]() ![]() "These patents reflect the company's important contributions to antibody technology research,'' stated R. 5,916,771, entitled: Production of a Multimeric Protein by Cell Fusion Method. Separately, Abgenix has also received a patent covering a new method for the generation of antibody manufacturing cell lines. Recent work published by Abgenix scientists showed that a humanized antibody produced in Xenomouse against human epidermal growth factor receptor prevented completely the formation of human epidermoid carcinoma A431 xenografts in athymic mice, and the eradication of established tumors without chemotherapy (reference 1). Any other human tissue or protein is thus recognized as a foreign antigen by the mouse and an immune response will be mounted. Importantly, these transgenic mice can generate antibodies to human antigens because the only human products expressed in the mice (and therefore recognized as "self") are the antibodies themselves. It enables efficient product development and flexibility in choosing manufacturing processes.It generates high affinity antibodies which do not require further engineering.It generates a diverse antibody response to essentially any disease target appropriate for antibody therapy.It produce antibodies with fully human protein sequences, reducing the possibility of human anti-mouse antibody response, observed in patients treated with monoclonal or chimeric antibodies.XenoMouse technology offers the following advantages: Hence, rather than engineering individual antibody molecules against specific antigens, a time-consuming and technically difficult process, XenoMouse technology has the animal do all the work, using the intact host immune system to generate a repertoire of high affinity antibodies. Into these host animals is transferred megabase-sized fragments from the human heavy and kappa light chain loci encompassing roughly 80% of the human immunoglobin gene in germ-line configuration, including some 34 of a possible 41 variable regions. However, unlike some related technologies that create chimeric or partly humanized proteins, the antibodies produced by these mice are 100% human protein.Ībgenix's approach to generating fully human antibodies employs genetically engineered strains of mice in which endogenous mouse antibody gene expression is suppressed by removing the J-chain, effectively disabling the antibody generating system of the host. These transgenic mouse strains, referred to as XenoMouse, make use of the natural power of the mouse immune system to respond to human disease targets by making multiple high affinity antibodies. 5,939,598, entitled: Method of Making Transgenic Mice Lacking Endogenous Heavy Chains. (Fremont, CA) has received a patent covering a key step used to generate transgenic mice that produce fully-human antibodies.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |